SCHEMBL477228

SCHEMBL477228

O=C(O)NN1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9727085 0.97 HTT (0.52)
Hydrochloric Acid SCHEMBL11600093 0.97 HTT (0.47)
SCHEMBL34638 0.97 HTT (0.52)
Benzene SCHEMBL3841909 0.95 HTT (0.55)
Hydrochloric Acid SCHEMBL8939931 0.95 HTT (0.50)
SCHEMBL1801925 0.94
Benzene SCHEMBL8030551 0.92 HTT (0.59)
SCHEMBL4615811 0.88
Pyrrolidine SCHEMBL25184622 0.86 HTT (0.40)
SCHEMBL18124344 0.86 HTT (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087903-A1 ANTIBODIES CONJUGATED TO CYCLOPROPYLBENZOINDOLE DIMER DRUG MOIETIES, AND METHODS OF USE AND TREATMENT Iksuda Therapeutics Limited (GB) 2026-04-30 WO disclosed
WO-2023202625-A1 FGFR2 INHIBITOR AND METHOD FOR USING SAME 深圳福沃药业有限公司 2023-10-26 WO disclosed
CN-111801100-B 7-substituted sulfoimidoyl purinone compounds and derivatives for the treatment and prevention of liver cancer 豪夫迈·罗氏有限公司 2023-10-24 CN disclosed
CN-112279786-B Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application 汤文建 2023-05-09 CN disclosed
US-20220363667-A1 T-TYPE CALCIUM CHANNEL BLOCKER NIPPON CHEMIPHAR CO., LTD. (JP) 2022-11-17 US disclosed
US-20220226299-A1 USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS NIPPON CHEMIPHAR CO., LTD. (JP) 2022-07-21 US disclosed
CN-112279786-A Cannabidiol carbamate compound, pharmaceutical preparation, preparation method and application 汤文建 2021-01-29 CN disclosed
CN-109020961-A Antiviral compound 吉利德制药有限责任公司 2018-12-18 CN disclosed
CN-104230900-B Antiviral compound 吉利德制药有限责任公司 2018-10-19 CN disclosed
US-20170204076-A1 SYNTHESIS AND USE OF AMINO LIPIDS SCREENFECT GMBH (DE) 2017-07-20 US disclosed
WO-2001098273-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2001-12-27 WO disclosed
WO-2000071534-A1 HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS ABBOTT LABORATORIES (US) 2000-11-30 WO disclosed
WO-2000061569-A1 ADAMANTANE DERIVATIVES ASTRAZENECA AB (SE) 2000-10-19 WO disclosed
EP-0671388-B1 (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments HOECHST MARION ROUSSEL INC (US) 1998-06-10 EP disclosed
US-5591856-A CHEMICAL INTERMEDIATES, TREATMENT OF ALZHEIMER'S DISEASE HOECHST ROUSSEL PHARMACEUTICALS INC. (US) 1997-01-07 US disclosed
US-5554750-A TO RELIEVE MEMORY DYSFUNCTIONS; TREATMENT OF ALZHEMER*S HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1996-09-10 US disclosed
EP-0671388-A1 (Pyrrolidinyl)phenyl carbamates and intermediate compounds, processes for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1995-09-13 EP disclosed
US-5405845-A Administering to relieve memory dysfunction; treatment of Alzheimer's disease HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1995-04-11 US disclosed
EP-0613892-A1 Cyclization and process for the preparation of N-cyclic and N,N'-dicylic ureas DSM Chemie Linz GmbH (AT) 1994-09-07 EP disclosed
US-5338739-A Memory dysfunction relieving compounds HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1994-08-16 US disclosed